Sign in
Taking people in United StatesNo phase

Studies how melanoma spreading under the skin changes over time

Studies skin melanoma nodules that spread away from the original tumor in adults.

Key facts

Who runs it
Yana Najjar
Where
Pittsburgh, United StatesSee the site
Trial code
Registry title
Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma
Status
Recruiting
People taking part
20 people, planned
Started
24 Feb 2021
Expected to end
31 Aug 2029
Type of study
Observational
Treatments tested
  • Pimonidazole
Record updated
11 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with melanoma who have at least two in-transit lesions at different distances from the first tumor, and whose lesions can be biopsied.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Melanoma (skin, mucosal or uveal) with at least two in-transit lesions at distinct distances from the primary site. A diagnosis of in-transit disease by the treating melanoma oncologist is enough.
Earlier treatment
People can be on treatment or not yet treated.

Main reasons for not taking part

  • In-transit disease that the treating doctor says cannot be biopsied
  • Known long-term immune suppression (for example remicade, mycophenolate, methotrexate, prednisone above 20 mg daily)
  • Known HIV, hepatitis B or hepatitis C infection

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Be willing and able to provide written informed consent for the trial
  • Be ≥ 18 years of age on day of signing informed consent
  • A histological diagnosis of melanoma and at least two in-transit lesions at distinct distances from the primary site. Patients may be enrolled on the basis of a diagnosis of in-transit disease by a treating melanoma oncologist
  • Cutaneous, mucosal or uveal melanoma are permitted
  • Patients may be on treatment or treatment naïve
  • Female patients of childbearing potential must have a negative urine or serum pregnancy test within 7 days from the time of pimonidazole administration

Who cannot take part

  • Subjects with in-transit disease that is not amenable to biopsy per the treating physician are excluded
  • Subjects who are known to be HIV+, Hep B or Hep C positive
  • Subjects with known chronic immunosuppression (such as biologic agents like remicade, mycophenolate, methotrexate, prednisone >20 mg daily)

Where in United States

  • UPMC Hillman Cancer CenterPittsburgh, United StatesContact: Amy Rose, RN, BSNTaking people

About the trial

What the trial wants to find out

Melanoma in-transit metastases (ITMs) continue to represent a therapeutic dilemma, in that no standard method of treatment has been uniformly adopted. The complexity and heterogeneity of patient and disease characteristics, including the location and number of ITMs presents a barrier to a one size fits all treatment approach. Treatment of patients with limited regional disease remains challenging. Patients are typically treated with a combination of surgery, regional therapy, systemic therapy. Data on the management of ITMs is limited, even with the availability of immunotherapy (IMT). This study will use the unique etiology of ITMs to facilitate the understanding of how individual lesions metabolically and immunologically evolve as they move away from the primary tumor site. It is hypothesize that as ITMs move away from the primary melanoma site each will harbor progressively hypermetabolic tumor cells and a harsher microenvironment.

The group in the trial

  • Pimonidazole

    Single dose of 0.5 gm/m\^2 of pimonidazole (approximately 13 mg/kg)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma
Plain-language title
Studies how melanoma spreading under the skin changes over timeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
11 June 2026